Diagnostic company Exact Sciences Corporation (NASDAQ:EXAS) reported Q2 CY2025 results exceeding the market’s revenue ...

Cathie Wood is one of the country's best known growth investors, but sometimes, she acts like an umbrella-toting value ...

Q2 2025 Earnings Call Transcript August 6, 2025 Exact Sciences Corporation beats earnings expectations. Reported EPS is $0.22 ...

Diagnostic company Exact Sciences Corporation (NASDAQ:EXAS) will be reporting earnings this Wednesday after market close.

Exact Sciences (NASDAQ:EXAS) said it has secured exclusive rights to both current and future iterations of Freenome’s ...

Baron Funds, an investment management company, released its “Baron Health Care Fund” second-quarter 2025 investor letter. A ...

Why Exact Sciences (EXAS) is a Top Growth Stock for the Long-Term July 24, 2025 — 09:45 am EDT Written by Zacks Equity Research for Zacks -> ...

GUARDANT HEALTH INC (NASDAQ: GH) faced a significant sell-off, with ARK parting with 1,419,766 shares for a total of approximately $63.31 million. This trade marks a notable exit from the precision ...

Debt Management: Exact Sciences's debt-to-equity ratio is below industry norms, indicating a sound financial structure with a ratio of 1.05. The Significance of Analyst Ratings Explained ...

Exact Sciences (EXAS) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

In trading on Tuesday, shares of EXACT Sciences Corp. (Symbol: EXAS) crossed above their 200 day moving average of $56.08, changing hands as high as $56.62 per share.

Exact Sciences Corporation (NASDAQ:EXAS) is one of the best mid cap pharma stocks to buy. On July 9, Exact Sciences announced that its Oncodetect molecular residual disease/MRD test received Medicare ...